My Health News Nevada
SEE OTHER BRANDS

Your health and wellness news from Nevada

My Health News Nevada: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Health News Nevada.

Press releases published on June 23, 2025

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE …

AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer

AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer

COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE ET DE NEUROPROTECTION CETTE …

 New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential

New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential

Press Release Carmil Therapeutics to develop next-generation immunotherapies based on this innovation Paris …

Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors

Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors

MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the appointment of two highly accomplished …

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Appoints Aaron Cox as Chief Financial Officer

Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership  Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …

Galapagos benoemt Aaron Cox als Chief Financial Officer

Galapagos benoemt Aaron Cox als Chief Financial Officer

Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - …

SBC Medical Participated in 4 Investor Conferences in May and June 2025

SBC Medical Participated in 4 Investor Conferences in May and June 2025

IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in several prominent investor conferences …

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity …

Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe

Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe

Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Recommandation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ajout de Sarclisa …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service